vs
MACROGENICS INC（MGNX）与REGIS CORP（RGS）财务数据对比。点击上方公司名可切换其他公司
REGIS CORP的季度营收约是MACROGENICS INC的1.4倍（$57.1M vs $41.2M），MACROGENICS INC同比增速更快（113.0% vs 22.3%），MACROGENICS INC自由现金流更多（$42.8M vs $891.0K），过去两年MACROGENICS INC的营收复合增速更高（112.8% vs 7.8%）
MacroGenics Inc是一家临床阶段生物制药公司，专注于研发针对癌症和自身免疫性疾病的新型免疫疗法，核心产品管线以单克隆抗体类治疗药物为核心，重点项目覆盖实体瘤与血液恶性肿瘤，通过与全球药企合作推进产品落地。
瑞吉斯公司是一家美国美发沙龙运营商，总部位于明尼苏达州明尼阿波利斯市。截至2021年8月，该集团旗下拥有5563家加盟沙龙以及276家直营门店，是北美地区规模领先的美发沙龙连锁经营企业。
MGNX vs RGS — 直观对比
营收规模更大
RGS
是对方的1.4倍
$41.2M
营收增速更快
MGNX
高出90.8%
22.3%
自由现金流更多
MGNX
多$41.9M
$891.0K
两年增速更快
MGNX
近两年复合增速
7.8%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $41.2M | $57.1M |
| 净利润 | — | $456.0K |
| 毛利率 | — | — |
| 营业利润率 | -29.3% | 10.8% |
| 净利率 | — | 0.8% |
| 营收同比 | 113.0% | 22.3% |
| 净利润同比 | — | -94.0% |
| 每股收益（稀释后） | $-0.23 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MGNXRGS
| Q4 25 | $41.2M | $57.1M | ||
| Q3 25 | $72.8M | $59.0M | ||
| Q2 25 | $22.2M | $60.4M | ||
| Q1 25 | $13.2M | $57.0M | ||
| Q4 24 | $19.4M | $46.7M | ||
| Q3 24 | $110.7M | $46.1M | ||
| Q2 24 | $10.8M | $49.4M | ||
| Q1 24 | $9.1M | $49.2M |
净利润MGNXRGS
| Q4 25 | — | $456.0K | ||
| Q3 25 | $16.8M | $1.4M | ||
| Q2 25 | $-36.3M | $116.5M | ||
| Q1 25 | $-41.0M | $250.0K | ||
| Q4 24 | — | $7.6M | ||
| Q3 24 | $56.3M | $-853.0K | ||
| Q2 24 | $-55.7M | $91.2M | ||
| Q1 24 | $-52.2M | $-2.3M |
毛利率MGNXRGS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 98.8% | — | ||
| Q3 24 | 99.8% | — | ||
| Q2 24 | 98.4% | — | ||
| Q1 24 | 97.0% | — |
营业利润率MGNXRGS
| Q4 25 | -29.3% | 10.8% | ||
| Q3 25 | 25.6% | 10.0% | ||
| Q2 25 | -165.3% | 12.1% | ||
| Q1 25 | -323.1% | 8.8% | ||
| Q4 24 | -273.0% | 11.8% | ||
| Q3 24 | 48.9% | 4.6% | ||
| Q2 24 | -538.9% | — | ||
| Q1 24 | -590.4% | 8.3% |
净利率MGNXRGS
| Q4 25 | — | 0.8% | ||
| Q3 25 | 23.1% | 2.3% | ||
| Q2 25 | -163.0% | 192.9% | ||
| Q1 25 | -311.1% | 0.4% | ||
| Q4 24 | — | 16.4% | ||
| Q3 24 | 50.9% | -1.9% | ||
| Q2 24 | -515.6% | 184.7% | ||
| Q1 24 | -573.3% | -4.7% |
每股收益（稀释后）MGNXRGS
| Q4 25 | $-0.23 | $0.16 | ||
| Q3 25 | $0.27 | $0.49 | ||
| Q2 25 | $-0.57 | $43.67 | ||
| Q1 25 | $-0.65 | $0.08 | ||
| Q4 24 | $-0.24 | $2.71 | ||
| Q3 24 | $0.90 | $-0.36 | ||
| Q2 24 | $-0.89 | $38.40 | ||
| Q1 24 | $-0.84 | $-1.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $57.2M | $18.4M |
| 总债务越低越好 | — | $113.3M |
| 股东权益账面价值 | $55.6M | $188.7M |
| 总资产 | $256.8M | $588.3M |
| 负债/权益比越低杠杆越低 | — | 0.60× |
8季度趋势，按日历期对齐
现金及短期投资MGNXRGS
| Q4 25 | $57.2M | $18.4M | ||
| Q3 25 | $80.1M | $16.6M | ||
| Q2 25 | $130.7M | $17.0M | ||
| Q1 25 | $145.6M | $13.3M | ||
| Q4 24 | $182.8M | $10.2M | ||
| Q3 24 | $179.6M | $6.3M | ||
| Q2 24 | $83.9M | $10.1M | ||
| Q1 24 | $80.4M | $5.9M |
总债务MGNXRGS
| Q4 25 | — | $113.3M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | — | $110.8M | ||
| Q1 25 | — | $112.0M | ||
| Q4 24 | — | $111.5M | ||
| Q3 24 | — | $95.2M | ||
| Q2 24 | — | $99.5M | ||
| Q1 24 | — | $179.7M |
股东权益MGNXRGS
| Q4 25 | $55.6M | $188.7M | ||
| Q3 25 | $67.0M | $187.6M | ||
| Q2 25 | $46.6M | $185.6M | ||
| Q1 25 | $79.1M | $68.6M | ||
| Q4 24 | $116.1M | $66.7M | ||
| Q3 24 | $120.1M | $56.4M | ||
| Q2 24 | $57.8M | $56.8M | ||
| Q1 24 | $106.2M | $-35.8M |
总资产MGNXRGS
| Q4 25 | $256.8M | $588.3M | ||
| Q3 25 | $270.8M | $592.1M | ||
| Q2 25 | $245.4M | $599.0M | ||
| Q1 25 | $224.6M | $511.2M | ||
| Q4 24 | $261.7M | $530.1M | ||
| Q3 24 | $264.5M | $508.9M | ||
| Q2 24 | $201.1M | $530.5M | ||
| Q1 24 | $248.3M | $543.7M |
负债/权益比MGNXRGS
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $43.0M | $1.7M |
| 自由现金流经营现金流 - 资本支出 | $42.8M | $891.0K |
| 自由现金流率自由现金流/营收 | 103.8% | 1.6% |
| 资本支出强度资本支出/营收 | 0.6% | 1.4% |
| 现金转化率经营现金流/净利润 | — | 3.65× |
| 过去12个月自由现金流最近4个季度 | $-83.0M | $14.9M |
8季度趋势，按日历期对齐
经营现金流MGNXRGS
| Q4 25 | $43.0M | $1.7M | ||
| Q3 25 | $-30.2M | $2.3M | ||
| Q2 25 | $-47.0M | $6.8M | ||
| Q1 25 | $-46.9M | $6.2M | ||
| Q4 24 | $-38.4M | $2.1M | ||
| Q3 24 | $60.2M | $-1.3M | ||
| Q2 24 | $-44.5M | $5.1M | ||
| Q1 24 | $-45.6M | $-277.0K |
自由现金流MGNXRGS
| Q4 25 | $42.8M | $891.0K | ||
| Q3 25 | $-30.6M | $1.9M | ||
| Q2 25 | $-47.7M | $6.2M | ||
| Q1 25 | $-47.4M | $5.9M | ||
| Q4 24 | $-39.0M | $1.7M | ||
| Q3 24 | $59.6M | $-1.4M | ||
| Q2 24 | $-45.5M | $5.1M | ||
| Q1 24 | $-47.1M | $-326.0K |
自由现金流率MGNXRGS
| Q4 25 | 103.8% | 1.6% | ||
| Q3 25 | -42.0% | 3.2% | ||
| Q2 25 | -214.5% | 10.3% | ||
| Q1 25 | -359.5% | 10.3% | ||
| Q4 24 | -201.7% | 3.6% | ||
| Q3 24 | 53.8% | -3.0% | ||
| Q2 24 | -421.6% | 10.3% | ||
| Q1 24 | -517.4% | -0.7% |
资本支出强度MGNXRGS
| Q4 25 | 0.6% | 1.4% | ||
| Q3 25 | 0.6% | 0.7% | ||
| Q2 25 | 3.2% | 0.9% | ||
| Q1 25 | 4.0% | 0.6% | ||
| Q4 24 | 3.2% | 0.9% | ||
| Q3 24 | 0.5% | 0.0% | ||
| Q2 24 | 9.6% | 0.0% | ||
| Q1 24 | 16.0% | 0.1% |
现金转化率MGNXRGS
| Q4 25 | — | 3.65× | ||
| Q3 25 | -1.79× | 1.68× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 24.80× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | 1.07× | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MGNX
| Revenue From Collaborative Agreements | $20.3M | 49% |
| Contract Manufacturing | $11.3M | 27% |
| Other | $9.7M | 23% |
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
